DiscoverRhinology Roundtable
Rhinology Roundtable
Claim Ownership

Rhinology Roundtable

Author: Ashleigh Halderman

Subscribed: 2Played: 17
Share

Description

Rhinology Roundtable: where expertise meets honesty, and the conversations go beyond the slides.

Rhinology Roundtable — brought to you by the American Rhinologic Society — is where the real conversations happen.

This isn’t another recap of what you already heard at national meetings or read in journals. Instead, Rhinology Roundtable pulls back the curtain on the unspoken, the under-discussed, and the clinically nuanced topics that shape everyday practice but rarely make it to the podium or the page.

Join candid, unscripted discussions between colleagues as they tackle high-yield clinical dilemmas, gray-zone decision-making, and the practical realities of rhinologic care. From controversial management strategies to “what we actually do” in clinic and the OR, this podcast delivers insights you won’t find in textbooks.

Whether you’re a seasoned rhinologist, a general otolaryngologist, or a trainee looking for real-world perspective, expect thoughtful debate, expert opinion, and actionable takeaways — all in a conversational format that feels like sitting in on a trusted peer discussion.

16 Episodes
Reverse
On this episode of Rhinology Roundtable, the podcast of the American Rhinologic Society, Dr. Ashleigh Halderman explores how allergies develop and how climate change and air pollution may be reshaping allergic disease. She reviews immune sensitization and tolerance, the difference between a positive allergy test and clinically relevant allergy, and the changing evidence around early exposures. The episode then examines shifting pollen seasons, extreme weather, and how pollution may affect both the nasal epithelial barrier and pollen itself. For clinical practice, the key message is to consider a patient’s symptoms, local exposures, and environmental context- not pollen counts or test results alone.Chapters·      0:25 – Welcome and episode introduction·      3.28 – Allergy basics and immune response·      7:19 – Why allergies develop·      12:39 – Peanut allergy and early exposure·      15:07 – Sensitization versus clinical allergy·      17::40 – Pollen seasons, geography, and migration·      22:18 – Climate change and pollen·      29:44 – Extreme weather and respiratory exposure·      34:18 – Air pollution and the nasal epithelial barrier·      39:09 – How pollution may alter pollen·      45:07 – Clinical implications and key takeaways
On this episode of Rhinology Roundtable, we explore how to successfully integrate advanced practice providers (APPs) into rhinology practices. Host Dr. Ashleigh Halderman speaks with members of the Rhinology Advance Practice Providers section of the ARS Emily Moldoff NP-C from Brigham and Women’s and Lindsay Wyant PA-C from Oregon Health Science University about the importance of defining the role before hiring and APP, providing structured, hands-on training and supportive feedback, and gradually building clinical independence. They also discuss the importance of trust, mentorship, professional development, and why retention depends on respect, autonomy, manageable workloads, and a genuine sense of partnership, not simply asking APPs to see more patients.  
Induction chemotherapy for sinonasal malignancies is not just "chemo before surgery" - it's a test of tumor biology, a chance to preserve critical structures, reduce morbidity, and sometimes the decision that determines what treatment comes next. Dr. Ashleigh Halderman is joined by Dr. Mat Geltzeiler from Oregon Health Science University and Dr. Garret Choby from the University of Pittsburgh Medical Center for a practical, high-stakes conversation about how leading experts actually think through the approach to treatment for these rare cancers. (Seriously, how many times can 3 people say “nuanced” in one conversation??) From SNUC and sinonasal squamous cell carcinoma to olfactory neuroblastoma, adenocarcinoma, and mucosal melanoma, they break down where induction helps, where it doesn't, and why histology and biomarkers are changing the entire playbook. You'll discover:Why induction means something different from neoadjuvant therapyWhen 2 cycles is enough, and when a third cycle changes everythingHow MRI, symptoms, and anatomic response all factor into reassessmentWhy non-responders may need a completely different strategyWhere immunotherapy fits in mucosal melanomaWhy SNUC is no longer one disease, and why that mattersThe conversation gets especially useful when the panel gets specific about real-world decision points: borderline resectability, orbital involvement, perineural spread, skull base disease, and the tradeoffs between a bigger surgery, chemoradiation, and quality of life. They also tackle the lingering uncertainty in the literature, including why randomized survival data are unlikely to ever be definitive in such rare tumors. This episode is essential listening for rhinologists, head and neck surgeons, medical and radiation oncologists, and trainees who want a clear framework for one of the most nuanced decisions in sinonasal oncology. If you manage complex skull base disease, or want to understand why the same diagnosis can lead to very different treatment paths, this one belongs on your playlist.
In this episode of Rhinology Roundtable, Dr. Ashleigh Halderman talks with Dr. Greg Davis and Dr. Leah Hauser about the expanding role of awake, in-office procedures in rhinology and otolaryngology. They discuss how to decide which procedures belong in the clinic or operating room, how to identify patients who are likely to tolerate office treatment, and the importance of thoughtful anesthesia, trained staff, consistent workflows, and protected scheduling. The conversation also explores the practical side of office-based care: reimbursement and insurance denials, patient comfort, and how procedure durability can differ between office and OR approaches. Their central message is that successful in-office care depends not only on the procedure itself, but also on honest conversations with patients and systems that make the work safe, repeatable, and sustainable. Advice From the EpisodeStart with low-risk, high-yield office procedures before expanding into more complex cases.Use a patient’s nasal endoscopy tolerance and general anxiety level as practical screening tools.Standardize room setup and teach staff the exact sequence for each procedure.Cluster procedure blocks so office work does not destabilize the entire clinic day.Check actual reimbursement after the procedure, not just the billed amount.Seek hands-on training in a lab or on asleep patients before performing a new office procedure on an awake patient.
Immunodeficiencies in SinusitisOn this episode of Rhinology Roundtable, host Dr. Ashleigh Halderman, and guests Dr. Angela Donaldson, and Dr. Sandra Lin discuss a topic where evidence-based guidance is sorely lacking. Topics covered include when to consider immune deficiency in a patient with either recurrent acute or chronic sinusitis, and why evaluating immunodeficiency requires more than checking a few lab values. They review the most common immunodeficiencies rhinologists/otolaryngologists should be aware of, timing of and length of antibiotic courses in acute sinusitis in patients with ID, the importance of culture-directed treatment, and options for treatment including topical antibiotics, immunoglobulin replacement, and the role of surgery.Key topicsWhich patients with either acute or chronic sinusitis may need to be considered for immune testingThe role of culture guided therapy for this unique patient populationThe role of CBC and quantitative IgG, IgA, and IgM testingWhy normal immunoglobulin levels do not exclude specific antibody deficiencyHow pneumococcal serotype testing and vaccine challenge assess immune functionWhen IgG subclasses are useful—and why they remain controversialHow rituximab, CAR T-cell therapy, transplant medications, and other treatments can cause secondary immune dysfunction and recurrent sinusitisHow immunodeficiency affects antibiotic choice, duration, and culture strategyWhen immunoglobulin replacement should be consideredWhy surgery may need to wait until immune therapy has had time to workHow surgery can improve drainage and access for topical treatment without curing the underlying immune problem but also improve quality of life and reduce the length and frequencies of episodesWhen more extensive procedures, such as mega antrostomy, may be appropriateKey takeawaysA single low immunoglobulin value is not enough to diagnose clinically significant immune deficiency.Functional antibody responses can reveal problems that quantitative testing misses.Recalcitrant sinus disease may reflect inflammation, infection, immune dysfunction, or a combination of all three.Surgery is an adjunctive treatment, not a cure, for patients with immune deficiency-related sinus disease.Patients with recurrent, severe, unusual, or treatment-resistant infections may warrant an immune evaluation. 
loading
Comments